Overview

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Status:
Unknown status

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel+cisplatin（TP) compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

Biotech Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Nimotuzumab
Paclitaxel